The Asia Pacific homeopathy market was valued at US$ 1,416.80 million in 2022 and is expected to reach US$ 4,443.39 million by 2030; it is estimated to grow at a CAGR of 15.4% from 2022 to 2030.
Based on type, the Asia Pacific homeopathy market is segmented into dilutions, tinctures, biochemics, ointments, tablets, and others. The dilutions segment held the largest market share in 2022.
Based on application, the Asia Pacific homeopathy market is segmented into analgesic and antipyretic, respiratory, neurology, immunology, gastroenterology, dermatology, and others. The immunology segment held the largest market share in 2022.
Based on distribution channel, the Asia Pacific homeopathy market is segmented into homeopathic clinics, retail pharmacies, e-retailers, and others. The homeopathic clinics segment held the largest market share in 2022.
Based on country, the Asia Pacific homeopathy market is segmented into Australia, Malaysia, India, Japan, New Zealand, and the Rest of Asia Pacific. India dominated the Asia Pacific homeopathy market share in 2022.
Fourrts; Boiron; Biologische Heilmittel Heel GmbH; DHU-Arzneimittel GmbH & Co. KG; Allen Healthcare Co., Ltd; and Dr Reckeweg & Co GmbH are some of the leading players operating in the Asia Pacific homeopathy market.
Safety Associated with Homeopathic Products fuel the Asia Pacific Homeopathy Market
Homeopathic medicines are widely considered safe as they are prescribed after special preparation processes. These involve the repeated steps of dilution and succussion of shaking at each dilution. Common potencies used are “30C,” diluted 1:100 30-times, and “200C,” diluted 1:100 20,000-times. Thus, such highly diluted medicines are prescribed by skilled professionals, which are deemed safe and are not likely to cause severe side effects. On December 6, 2022, FDA issued a final guidance, Homeopathic Drug Products, that describes the agency’s approach to prioritizing regulatory actions for homeopathic products posing the greatest risk to patients. The FDA is prioritizing specific categories of drugs, such as those intended for populations at greater risk for adverse reactions.Asia Pacific Homeopathy Market Overview
The homeopathy market in Asia Pacific is segmented into Japan, India, Australia, Malaysia, New Zealand, and the Rest of Asia Pacific. Rising demand for alternative medicine is driving the growth of the market. The increasing prevalence of lifestyle diseases such as heart disease, stroke, obesity, and type 2 diabetes are further boosting the market growth in the region.Asia Pacific Homeopathy Market Revenue and Forecast to 2030 (US$ Million)
Asia Pacific Homeopathy Market Segmentation
The Asia Pacific homeopathy market is segmented based on source, type, application, distribution channel, and country. Based on sources, the Asia Pacific homeopathy market is segmented into plants, animals, and minerals. The plants segment held the largest market share in 2022.Based on type, the Asia Pacific homeopathy market is segmented into dilutions, tinctures, biochemics, ointments, tablets, and others. The dilutions segment held the largest market share in 2022.
Based on application, the Asia Pacific homeopathy market is segmented into analgesic and antipyretic, respiratory, neurology, immunology, gastroenterology, dermatology, and others. The immunology segment held the largest market share in 2022.
Based on distribution channel, the Asia Pacific homeopathy market is segmented into homeopathic clinics, retail pharmacies, e-retailers, and others. The homeopathic clinics segment held the largest market share in 2022.
Based on country, the Asia Pacific homeopathy market is segmented into Australia, Malaysia, India, Japan, New Zealand, and the Rest of Asia Pacific. India dominated the Asia Pacific homeopathy market share in 2022.
Fourrts; Boiron; Biologische Heilmittel Heel GmbH; DHU-Arzneimittel GmbH & Co. KG; Allen Healthcare Co., Ltd; and Dr Reckeweg & Co GmbH are some of the leading players operating in the Asia Pacific homeopathy market.
Table of Contents
1. Introduction
2. Executive Summary
3. Research Methodology
4. Asia Pacific Homeopathy Market - Key Industry Dynamics
5. Homeopathy Market - Asia Pacific Market Analysis
6. Asia Pacific Homeopathy Market - Revenue and Forecast to 2030 - by Source
7. Asia Pacific Homeopathy Market - Revenue and Forecast to 2030 - by Type
8. Asia Pacific Homeopathy Market - Revenue and Forecast to 2030 - by Application.
9. Asia Pacific Homeopathy Market - Revenue and Forecast to 2030 - by Distribution Channel
10. Asia Pacific Homeopathy Market - Revenue and Forecast to 2030 - Country Analysis
11. Homeopathy Market-Industry Landscape
12. Company Profiles
13. Appendix
List of Tables
List of Figures
Executive Summary
At 15.4% CAGR, the Asia Pacific Homeopathy Market is Speculated to be worth US$ 4,443.39 million by 2030.According to this research,, the Asia Pacific homeopathy market was valued at US 1,416.80 million in 2022 and is expected to reach US$ 4,443.39 million by 2030, registering a CAGR of 15.4% from 2022 to 2030. Safety associated with homeopathic products and rise in adoption of homeopathic medicine are the critical factors attributed to the Asia Pacific homeopathy market expansion.
There are growing concerns about the potential side effects of allopathic pharmaceutical drugs or regular medication. In Asian countries, consumers have been turning to alternative medicines, such as natural remedies, homeopathy, and herbal medicines. Some skilled homeopaths have also been promoting the benefits of alternative medicines, especially to patients suffering from chronic health conditions such as cardiovascular disease and cancer. A study published in the Scandinavian Journal of Public Health in 2017 stated that alternative practices are primarily used in a complementary manner or in combination with traditional medicine. For instance, Curcuma longa (turmeric), a traditional form of medicine that originates from India, is one of the natural ingredients that is steeped in homeopathy. The preference for orally administered medications and drugs without any side effects has been on the rise for a long, and it would continue to grow in the coming years. Allopathy contains strong medications; however, they are not appropriate for everyone. Furthermore, allopathic drugs are expensive and only have a transient effect on illnesses. Moreover, despite the completion of the course of prescribed drugs, the illness can resurface. Cases of drug abuse are more common with allopathic medicines, which is another factor for the shifting focus toward natural medications. Homeopathy remedies, on the other hand, are inexpensive and exhibit no or negligible side effects. Thus, the increasing adoption of homeopathic medicine bolsters the homeopathy market growth. This is expected to drive the Asia Pacific homeopathy market during the forecast period.
On the contrary, stringent approach by regulatory authorities and shortage of homeopathic facilities & doctors hurdles the growth of Asia Pacific homeopathy market.
Based on source, the Asia Pacific homeopathy market is categorized into plants, animals, and minerals. The plants segment held 61.5% market share in 2022, amassing US$ 870.96 million. It is projected to garner US$ 2,759.75 million by 2030 to expand at 15.5% CAGR during 2022-2030.
Based on type, the Asia Pacific homeopathy market is categorized into dilutions, tinctures, biochemics, ointments, tablets, and others. The dilutions segment held 26.0% share of Asia Pacific homeopathy market in 2022, amassing US$ 367.78 million. It is projected to garner US$ 1,139.13 million by 2030 to expand at 15.2% CAGR during 2022-2030.
Based on application, the Asia Pacific homeopathy market is categorized into analgesic and antipyretic, respiratory, neurology, immunology, gastroenterology, dermatology, and others. The immunology segment held 24.2% share of Asia Pacific homeopathy market in 2022, amassing US$ 342.55 million. It is projected to garner US$ 1,124.85 million by 2030 to expand at 16.0% CAGR during 2022-2030.
Based on distribution channel, the Asia Pacific homeopathy market is categorized into homeopathic clinics, retail pharmacies, e-retailers, and others. The homeopathic clinics segment held 35.3% share of Asia Pacific homeopathy market in 2022, amassing US$ 499.91 million. It is projected to garner US$ 1,615.41 million by 2030 to expand at 15.8% CAGR during 2022-2030.
Based on country, the Asia Pacific homeopathy market has been categorized into Australia, Malaysia, India, Japan, New Zealand, and the Rest of Asia Pacific. Our regional analysis states that India captured 24.5% share of Asia Pacific homeopathy market in 2022. It was assessed at US$ 346.41 million in 2022 and is likely to hit US$ 1,125.51 million by 2030, exhibiting a CAGR of 15.9% during 2022-2030.
Key players operating in the Asia Pacific homeopathy market are Fourrts; Boiron; Biologische Heilmittel Heel GmbH; DHU-Arzneimittel GmbH & Co. KG; Allen Healthcare Co. Ltd., and Dr Reckeweg & Co GmbH among others.
In Mar 2022, New pharmaceutical production for homeopathic manufacturer Dr. Reckeweg. In May 2020, Fourrts marketed Arsenicum Album 30C against COVID.
Companies Mentioned
- Biologische Heilmittel Heel GmbH
- Boiron
- DHU-Arzneimittel GmbH & Co. KG
- Dr Reckeweg & Co GmbH
- Fourrts
- Allen Healthcare Co. Ltd.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 94 |
| Published | December 2023 |
| Forecast Period | 2022 - 2030 |
| Estimated Market Value in 2022 | 1.42 Billion |
| Forecasted Market Value by 2030 | 4.44 Billion |
| Compound Annual Growth Rate | 15.4% |
| Regions Covered | Asia Pacific |
| No. of Companies Mentioned | 6 |
